VSTM
Verastem, Inc.
Key Financials
Revenue
$30.9M
↑ 209.1%
Net Income
$-209471000
↓ 60.3%
Operating Income
$-170129000
↓ 48.0%
Total Assets
$246.4M
↑ 142.7%
Total Liabilities
$189.2M
↑ 45.1%
EPS (Diluted)
$-3.02
↑ 17.5%
Shareholders' Equity
$57.2M
↑ 298.0%
Cash & Equivalents
$205.0M
↑ 130.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| 8-K | 8/7/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| SCHEDULE 13G | 7/31/2026 | View on SEC |
| SCHEDULE 13G/A | 7/30/2026 | View on SEC |
| 144 | 7/23/2026 | View on SEC |
| SCHEDULE 13G/A | 7/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VSTM |
| Company Name | Verastem, Inc. |
| CIK | 1526119 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | MA |
| Phone | (781) 292-4200 |